Tags

Type your tag names separated by a space and hit enter

Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy.
Dan Med J 2015; 62(1):A4999DM

Abstract

INTRODUCTION

Treatment of severe spasticity and dystonia with intrathecal baclofen (ITB) in children has been shown to be effective and has therefore been employed in the Region of Southern Denmark. The aim of this retrospective study was to analyse the efficacy and adverse events since ITB was introduced in 2003.

METHODS

A total of 46 children who had a baclofen pump from April 2003 to January 2013 were included. The children's medical records were reviewed and clinical characteristics, efficacy and adverse events were registered. The efficacy of treatment experienced by parents was ascertained by telephone interviews, and data were rated on a Likert scale ranging from one to five, where one was no effect and five was marked improvement.

RESULTS

After ITB, spasticity was reduced from a median of four to two in the upper extremities and from a median of four to one in the lower extremities. Baclofen infusion was 105.1-2,000 micrograms/day (mean 494.9 micrograms/day). Oral baclofen was reduced from 27.3 to 17.7 mg/day after ITB (p < 0.01). The parents' assessment of improvement in well-being, function and ease of care of their child had a mean score of 3.7, 2.2 and 3.4, respectively. 87.1% of parents stated that ITB had been worthwhile, and 90.3% would recommend it to other parents. Most infectious and mechanical adverse events were experienced during the first 200 days after pump implantation. The total complication rate was 0.40 per pump year.

CONCLUSION

ITB resulted in reduced spasticity in children with severe spasticity and dystonia, and ITB could be considered safe. Parents' satisfaction with ITB was rated as good and most parents would recommend ITB to others.

FUNDING

not relevant.

TRIAL REGISTRATION

not relevant.

Authors+Show Affiliations

Psykiatrisk Afdeling, Odense Universitetshospital, Kløvervænget 25, 5000 Odense C, Denmark. tinett.overgard@rsyd.dk.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25557334

Citation

Overgård, Tinett Martesen, et al. "Positive Experience With Intrathecal Baclofen Treatment in Children With Severe Cerebral Palsy." Danish Medical Journal, vol. 62, no. 1, 2015, pp. A4999.
Overgård TM, Kjærsgaard-Hansen L, Søe M, et al. Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy. Dan Med J. 2015;62(1):A4999.
Overgård, T. M., Kjærsgaard-Hansen, L., Søe, M., & Illum, N. O. (2015). Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy. Danish Medical Journal, 62(1), pp. A4999.
Overgård TM, et al. Positive Experience With Intrathecal Baclofen Treatment in Children With Severe Cerebral Palsy. Dan Med J. 2015;62(1):A4999. PubMed PMID: 25557334.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Positive experience with intrathecal baclofen treatment in children with severe cerebral palsy. AU - Overgård,Tinett Martesen, AU - Kjærsgaard-Hansen,Lars, AU - Søe,Morten, AU - Illum,Niels Ove, PY - 2015/1/6/entrez PY - 2015/1/6/pubmed PY - 2015/8/12/medline SP - A4999 EP - A4999 JF - Danish medical journal JO - Dan Med J VL - 62 IS - 1 N2 - INTRODUCTION: Treatment of severe spasticity and dystonia with intrathecal baclofen (ITB) in children has been shown to be effective and has therefore been employed in the Region of Southern Denmark. The aim of this retrospective study was to analyse the efficacy and adverse events since ITB was introduced in 2003. METHODS: A total of 46 children who had a baclofen pump from April 2003 to January 2013 were included. The children's medical records were reviewed and clinical characteristics, efficacy and adverse events were registered. The efficacy of treatment experienced by parents was ascertained by telephone interviews, and data were rated on a Likert scale ranging from one to five, where one was no effect and five was marked improvement. RESULTS: After ITB, spasticity was reduced from a median of four to two in the upper extremities and from a median of four to one in the lower extremities. Baclofen infusion was 105.1-2,000 micrograms/day (mean 494.9 micrograms/day). Oral baclofen was reduced from 27.3 to 17.7 mg/day after ITB (p < 0.01). The parents' assessment of improvement in well-being, function and ease of care of their child had a mean score of 3.7, 2.2 and 3.4, respectively. 87.1% of parents stated that ITB had been worthwhile, and 90.3% would recommend it to other parents. Most infectious and mechanical adverse events were experienced during the first 200 days after pump implantation. The total complication rate was 0.40 per pump year. CONCLUSION: ITB resulted in reduced spasticity in children with severe spasticity and dystonia, and ITB could be considered safe. Parents' satisfaction with ITB was rated as good and most parents would recommend ITB to others. FUNDING: not relevant. TRIAL REGISTRATION: not relevant. SN - 2245-1919 UR - https://www.unboundmedicine.com/medline/citation/25557334/Positive_experience_with_intrathecal_baclofen_treatment_in_children_with_severe_cerebral_palsy_ L2 - http://ugeskriftet.dk/dmj/A4999 DB - PRIME DP - Unbound Medicine ER -